The specific price situation of Bosutinib

Bosutinib is an oral, second-generation tyrosine kinase inhibitor (TKI) that targets Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). This drug was developed by Pfizer and is another important targeted drug after imatinib and dasatinib. Its emergence is mainly to solve the problem of drug resistance or intolerance in some patients after long-term use of previous generations of TKIs. Bosutinib inhibits leukemia cell proliferation and promotes apoptosis by inhibiting BCR-ABL kinase activity and blocking abnormal cell signaling pathways.

Compared with early targeted drugs, bosutinib has higher selectivity and lower risk of cross-resistance, and is especially suitable for patients who are resistant to otherTKIs. In addition, bosutinib also has an inhibitory effect on Src family kinases, which gives it a unique advantage in overcoming certain complex drug-resistant mutations.

In terms of price, since the original drug of bosutinib has not yet been officially launched in mainland China, the current domestic price has not been disclosed. According to overseas market data, original research versions are sold in Switzerland, Europe, Türkiye and other places. The common specifications are 500mg and 28 tablets. The Turkish version sells for about RMB 2,000 per box, while the European and Swiss versions may cost around RMB 40,000. The specific price is greatly affected by exchange rate fluctuations and channel differences.

In addition, countries such as India and Bangladesh have produced generic versions. The drug ingredients are basically the same as the original drugs, but the price is more affordable. For example, the Indian version120 tablets of 100mg are sold for about RMB 1,000 to 2,000. With the popularity of generic drugs, bosutinib's accessibility is gradually increasing globally. In the future, if original research drugs are introduced into the country or included in medical insurance, it will further reduce the financial burden on patients and allow more patients with chronic myelogenous leukemia to benefit from precise targeted therapy.

Reference materials:https://go.drugbank.com/drugs/DB06616